COMMUNIQUÉS West-GlobeNewswire

Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
13/05/2024
- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP) - ASGCT poster presentations described immune-quiet DNA ( [...]
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
13/05/2024
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on [...]
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
13/05/2024
Company to host call at 4:30pm today NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel [...]
NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year
13/05/2024
LANGHORNE, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer [...]
Stereotaxis Reports 2024 First Quarter Financial Results
13/05/2024
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first [...]
Augmedix Delivers 40% Revenue Growth for First Quarter of 2024
13/05/2024
SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. “ [...]
Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies
13/05/2024
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a [...]
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
13/05/2024
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12 [...]
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
13/05/2024
- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks - - Development [...]
Cara Therapeutics Reports First Quarter 2024 Financial Results
13/05/2024
Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. ( [...]
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
13/05/2024
DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality [...]
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
13/05/2024
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Marc Elia, [...]
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
13/05/2024
Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b [...]
Teknova Reports First Quarter 2024 Financial Results
13/05/2024
First quarter 2024 total revenue was $9.3 million, up 2% from prior year Launch of Build-Tek™ Custom Configurator Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., May 13, 2024 (GLOBE NEWSWIRE [...]
Assure & Danam to Host Corporate Update Call & Webcast
13/05/2024
DENVER, May 13, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, announced today that [...]
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
13/05/2024
Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and [...]
AVITA Medical Reports First Quarter Financial Results
13/05/2024
VALENCIA, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]
Akoya Biosciences Reports First Quarter 2024 Financial Results
13/05/2024
MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the first quarter ending March 31, 2024. [...]
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
13/05/2024
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta [...]

Pages